Prognostic factors of recurrent respiratory papillomatosis from a registry of 72 patients.
CONCLUSIONS
The database revealed severity factors relating to human papillomavirus (HPV) type and age at diagnosis. While not exhaustive, the database is easy to use and could serve for a European multicentre epidemiological study.


OBJECTIVE
To propose a database as a starting point for a national registry and to estimate prognostic factors in recurrent respiratory papillomatosis (RRP).


METHODS
This was a retrospective study carried out in a tertiary care teaching hospital. From January 2005 to July 2007, epidemiological, clinical and treatment information on patients undergoing endoscopy for RRP in the department was entered in a database. Data were collected on three forms: the first comprised information about disease history before assessment in the department, the second about the disease and its treatment in the department, and the third about evolution after treatment.


RESULTS
Data on 72 patients were entered into an RRP database between January 2005 and July 2007. In all, 82% had already been treated for RRP in a different centre; 24 had juvenile-onset (JORRP) and 48 adult-onset (AORRP) papillomatosis. Cidovir injections had been administered to 91% of the patients. Histology found nine cases of dysplasia, one of carcinoma in situ and one of invasive carcinoma. Subglottic and tracheal locations were significantly more frequent in JORRP than in AORRP, as were the maximum Derkay scores and annual numbers of endoscopies. Patients with type 11 HPV had significantly more endoscopies per year than those with type 6.
Carvalho
Christine Martins
CM
Département d'Oto-Rhino-Laryngologie, Hôpital Edouard Herriot, Lyon, France. martinscarvalho@aliceadsl.fr
Huot
Laure
L
Charlois
Anne-Laure
AL
Khalfallah
Sonia Ayari
SA
Chapuis
Francois
F
Froehlich
Patrick
P
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D000077404:Cidofovir; D003596:Cytosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016208:Databases, Factual; D005260:Female; D005602:France / Q000453:epidemiology; D006784:Hospitals, Teaching; D052140:Human papillomavirus 11 / Q000302:isolation & purification; D052163:Human papillomavirus 6 / Q000302:isolation & purification; D006801:Humans; D007828:Laryngoscopy; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use; D010212:Papilloma / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy / Q000821:virology; D030361:Papillomavirus Infections / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D011379:Prognosis; D012042:Registries; D012142:Respiratory Tract Neoplasms / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy / Q000821:virology; D012189:Retrospective Studies
D000970:Antineoplastic Agents; D063065:Organophosphonates; D003596:Cytosine; D000077404:Cidofovir